On June 12, Futu News reported that $QUANTUMPH-P (02228.HK)$Today's pre-market trading opened flat, up 2.08%, at HKD 5.39, with a turnover of HKD 11.29 million and a total market value of HKD 18.363 billion. Each lot contains 1000 shares, without considering handling fees, earning HKD 110 per lot.
Market source: Futu Securities >
Investment highlights
Advantage in csi leading technology index: Crystal Technology has a globally leading platform for quantum physics and artificial intelligence enabled drug and material science research and development. The company was the first to apply quantum physics-based computing, artificial intelligence, and automation technology with expertise in drug research and development to design and develop drugs and new materials, including biomaterials, new agricultural technology applications, new chemical surfactants and catalysts, as well as cosmetics and health products. At the same time, Crystal Technology's comprehensive technology platform integrates computer-style tools empowered by high-performance cloud computing, including first-principles calculations based on quantum physics and artificial intelligence, for dry lab calculations and evaluations, and robot automation for wet lab experiments. As of the last feasible date, the company's comprehensive technology platform has used more than 700 million core hours of cloud computing, and the company has contributed to more than 500 projects, including drug discovery and solid-state development projects.
Global strategy and customer base: Crystal Technology has established strategic partnership with many well-known biotechnology and pharmaceutical conglomerates, national research institutions and government departments worldwide, including pfizer, cklife sciences and Experimental Drug Development Center (EDDC) (Singapore National Drug Design and Discovery Platform). As of the last feasible date, the company has provided services to more than 300 biotechnology and pharmaceutical companies and research institutions worldwide, including 16 of the top 20 biotechnology and pharmaceutical companies (by 2022 revenue). In 2021, 2022 and 2023, Crystal Technology's customer retention rate was approximately 67.5%, 51.4% and 64.9%, respectively.
Risk warning
The commercial success of Crystal Technology largely depends on the market acceptance of its closed-loop comprehensive technology platform and technological capabilities. If the company cannot maintain its technological advantages or its platform and technology promotion fails to gain market recognition, it may have significant adverse effects on the company's commercial success.
Crystal Technology's business operations are subject to strict international regulatory environment, especially in jurisdictions related to drug research and development. The company needs to comply with multiple laws and regulations including cybersecurity, data protection, privacy and critical information infrastructure protection. Failure to comply with these regulations may expose the company to risks such as administrative penalties, fines, business suspensions or license revocations.
Futu offers new stock subscription, with zero commission. Get ahead of the game by buying in pre-market.Come and experience it now>>
Editor/Lily